Clinical trial
A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusion in Female and Male Participants Aged 18 Years of Age and Older With Refractory/Relapsing B-Cell Malignancies
NCT06539338 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusion in Female and Male Participants Aged 18 Years of Age and Older With Refractory/Relapsing B-Cell Malignancies
- Lead sponsor
- Kite, A Gilead Company
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- September 20, 2024
- Completion date
- October 31, 2026
- Enrollment
- 10 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
lymphomas non-hodgkin's b-cell, precursor cell lymphoblastic leukemia-lymphoma